Form4insider filings, from the source

SEC Form 3 · accession 0001104659-18-051570

Aridis Pharmaceuticals, Inc. · ARDS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Vu Truong
Officer — CEO, CSO, Director · Director · 10% Owner
Period of report
Aug 13, 2018
Accepted (ET)
Aug 13, 2018 · 7:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001614067

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———732,352D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock OptionsF1$2.89holding————Mar 16, 2025Common Stock77,908—D
Stock OptionsF2$12.96holding————Dec 4, 2025Common Stock23,373—D
Stock Options$13.16holding———Mar 1, 2017Oct 26, 2026Common Stock23,373—D
Stock OptionsF3$17.01holding————Dec 5, 2027Common Stock116,861—D

Explanation of responses